JCS/T2D JCS/T2D
JCS/T2D JCS/T2D
  • Home
  • About
  • Disclaimer
  • Privacy
  • Search
  • Contact Us
  • The Economic Impact of Weight-Loss Drugs: A Trillion-Dollar Boost?

  • The Potential of GLP-1 Medications for Type 1 Diabetes

  • The Surprising Mental Health Benefits of GLP-1 Medications for Diabetes and Obesity

  • Understanding Incretin Receptor Signaling Bias and Its Potential in Treating Obesity and Type 2 Diabetes

  • Understanding the Link Between GLP-1 Receptor Agonists and Reduced Colorectal Cancer Risk in Type 2 Diabetes Patients

  • Unlocking Heart Health: The SELECT Trial Sheds Light on the Cardiovascular Benefits of Semaglutide Beyond Weight Loss

  • Wegovy’s Lowest Dose Now Available in the U.S.

Page 2 of 2

  • 1
  • 2
  • You are here:  
  • Home
  • Tags
  • GLP-1
 

JCS/T2D

We are advocates. We learn. We share. We inform.
Bringing clarity to type 2 diabetes, obesity care, health research, and the data behind them.

Content is provided for educational and informational purposes and is not medical advice.

Helpful Links

About Us
Contact Us
JCS Analytics

Copyright © 2026 JCS/T2D - A Diabetes Journey. All Rights Reserved.
Joomla! is Free Software released under the GNU General Public License.